HealthSouth Risk/Reward Profile Grows Worse
Barclays' Joshua Raskin has downgraded HealthSouth Corp (NYSE: HLS) to Underweight from Equal Weight on unfavorable risk/reward.
Following are Raskin's seven reasons for the downgrade:
- "We believe there is increasing scrutiny around IRF payments in the Medicare program, including updated MedPAC pressures."
- "Medicare Advantage historically has not utilized services at HealthSouth at the same rate as Medicare FFS."
- "Acquisitions continue to obscure unimpressive organic growth for the IRF segment."
- "Leverage is up substantially over the past 1.5 years as a result of the company's recent acquisitions of CareSouth, Reliant and Encompass."
- "We believe the cross-selling opportunity between the inpatient rehab segment and home-health segment is overstated."
- "Based on HealthSouth's current valuation and our outlook for 2016 and 2017, we believe there is little room for multiple expansion."
- "We believe the CJR payment model presents a potential risk for HealthSouth."
Meanwhile, Raskin has cut the price target by $3 to $42, while maintaining the full-year EPS at $2.45.
At the time of writing, shares of HealthSouth fell 3.13 percent to $38.32.
Latest Ratings for HLS
Date | Firm | Action | From | To |
---|---|---|---|---|
Nov 2017 | William Blair | Initiates Coverage On | Outperform | |
Nov 2017 | Mizuho | Upgrades | Neutral | Buy |
Aug 2017 | Stephens & Co. | Initiates Coverage On | Overweight |
View More Analyst Ratings for HLS
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Analyst Color Short Ideas Downgrades Health Care Price Target Analyst Ratings Trading Ideas General